← Evidence map

ArticleFrontiers in immunology2025

PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database.

Alexandre O Gérard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

3 papers cite it

2025

this papercites it

PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database. | OpenQuestion